Key Highlights
- Shares of Amylyx surged approximately 21% during pre-market hours following successful Phase 3 results for avexitide, a GLP-1 receptor antagonist
- Participants in the LUCIDITY trial experienced 55% fewer severe low blood sugar episodes versus those receiving placebo
- Mizuho Securities upgraded its AMLX price target from $24 to $30 while maintaining an Outperform rating
- The drug has received both FDA Breakthrough Therapy and Orphan Drug Designations
- Company aims for a 2027 market entry and has begun preliminary work on its New Drug Application
Shares of Amylyx Pharmaceuticals experienced a significant rally of approximately 21% during Tuesday’s pre-market session following the company’s disclosure that avexitide, its experimental GLP-1 receptor antagonist, achieved success in a pivotal late-stage clinical study. The biotech stock reached $26.76 in pre-market activity, surpassing its previous 52-week peak of $24.60.
Amylyx Pharmaceuticals, Inc., AMLX
The LUCIDITY Phase 3 study represented a 16-week investigation conducted across multiple centers using a randomized, double-blind, placebo-controlled design with 78 enrolled subjects. The research evaluated avexitide’s effectiveness in treating post-bariatric hypoglycemia, a serious metabolic complication characterized by dangerously low blood glucose levels following food consumption, typically emerging years after bariatric surgical procedures.
The study successfully achieved its primary objective, which had received prior regulatory alignment. Participants receiving avexitide experienced 55% fewer episodes of severe hypoglycemia compared to the placebo group.
Additionally, avexitide demonstrated positive outcomes across all secondary measures. These encompassed data gathered through both patient-administered fingerstick glucose tests and continuous glucose monitoring systems.
The mechanism of action for avexitide differs fundamentally from popular GLP-1 agonist medications such as Wegovy and Zepbound. Instead of mimicking GLP-1 hormone activity to reduce blood glucose, avexitide functions as an antagonist, blocking GLP-1 receptors located on pancreatic cells to prevent excessive hormonal signaling following meal intake.
Analyst Price Target Increase
Prior to the data release, Mizuho Securities elevated its price objective for AMLX from $24 to $30 while reaffirming its Outperform recommendation. The investment firm also designated the stock as a premier 2026 selection and projected a possible appreciation of $10 to $15 from existing levels contingent on favorable Phase 3 outcomes.
The FDA has granted avexitide both Breakthrough Therapy Designation and Orphan Drug status, regulatory classifications that may facilitate an accelerated approval process.
According to Amylyx, preliminary activities related to NDA submission readiness have commenced. The company is targeting a commercial debut in 2027.
Broader Market Backdrop
The positive movement occurred against challenging conditions in the wider equity markets. Pre-market indicators showed the Nasdaq declining 1.2% while the S&P 500 retreated 0.5%. Biotechnology stocks generally faced pressure during the session.
Company executives convened a conference call at 8:00 a.m. Eastern Time on Tuesday to review the trial outcomes with investors and analysts.
Amylyx had initially projected a broader Q3 2026 window for data disclosure. Tuesday’s release represented an acceleration of that timeline.
The pre-market valuation of $26.76 for AMLX shares represented a decisive break above the stock’s former 52-week high of $24.60.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
